Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tilray BrandsTLRY -2.76%51 EV-to-EBITDA is -0.41 as of Jul. 25, 2026. GuruFocus rates TLRY with a GF Score™ of 51/100 and a GF Value™ of $12.50 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 742 Drug Manufacturers companies, Tilray Brands ranks worse than 134770.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Tilray Brands's enterprise value is $544.4 Mil.
Tilray Brands's EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 was $-1,342.3 Mil. Therefore, Tilray Brands's EV-to-EBITDA for today is -0.41.
The historical rank and industry rank for Tilray Brands's EV-to-EBITDA or its related term are showing as below:
TLRY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -174.44 Med: -1.21 Max: 42528.23
Current: -0.41
During the past 13 years, the highest EV-to-EBITDA of Tilray Brands was 42528.23. The lowest was -174.44. And the median was -1.21.
TLRY's EV-to-EBITDA is ranked worse than 100% of 742
companies
in the Drug Manufacturers industry
Industry Median: 12.96
vs TLRY: -0.41
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Tilray Brands (NAS:TLRY) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Tilray Brands's PE Ratio (TTM) for today is calculated as:
Tilray Brands's share price for today is $3.88.
Tilray Brands's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.650.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Tilray Brands's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tilray Brands's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tilray Brands EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tilray Brands's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tilray Brands's EV-to-EBITDA falls into.
Tilray Brands's current Enterprise Value is $544.4 Mil.
Tilray Brands's EBITDA for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,342.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tilray Brands (TLRY) has a EV-to-EBITDA of -0.41 as of Jul. 25, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tilray Brands. According to the industry distribution chart, Tilray Brands ranks #999999 out of 742 companies in the Drug Manufacturers industry.
Is Tilray Brands' EV-to-EBITDA too high?
Tilray Brands' current EV-to-EBITDA is -0.41. Based on the distribution chart, Tilray Brands ranks #999999 out of 742 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Tilray Brands has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tilray Brands' EV-to-EBITDA compare to AQST and EOLS?
According to the Drug Manufacturers industry distribution chart, Tilray Brands ranks #999999 out of 742 companies for EV-to-EBITDA. This places Tilray Brands in the lower half of its industry. The industry median EV-to-EBITDA is 12.96. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 12.96, based on 742 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Tilray Brands. For the Drug Manufacturers industry, the median EV-to-EBITDA is 12.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tilray Brands's current EV-to-EBITDA is -0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tilray Brands stock overvalued right now?
Based on GuruFocus' analysis, Tilray Brands (TLRY) is currently considered Possible Value Trap. The stock's GF Value™ is $12.50, compared to a current price of $3.88 — trading 69% below its estimated fair value. The current EV-to-EBITDA is -0.41. Tilray Brands' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Tilray Brands (TLRY), the current EV-to-EBITDA is -0.41 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tilray Brands (TLRY) Overvalued in 2026?
Based on GuruFocus' analysis, Tilray Brands stock appears to be undervalued.
The current stock price of $3.88 is trading 69% below its estimated GF Value™ of $12.50.
GuruFocus considers Tilray Brands to be Possible Value Trap.
Key valuation signals for TLRY:
EV-to-EBITDA: -0.41
GF Value™: $12.50 vs. price of $3.88 (69% below fair value)
No single metric tells the full story. See the TLRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
51GF Score
Get the complete analysis for TLRY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TLRY has been successfully added to your 
